Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue The Lancet Neurology Année : 2015

Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial

Fichier non déposé

Dates et versions

inserm-02456704 , version 1 (13-06-2023)

Identifiants

Citer

Ronit Pressler, Geraldine Boylan, Neil Marlow, Mats Blennow, Catherine Chiron, et al.. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. The Lancet Neurology, 2015, 14 (5), pp.469-477. ⟨10.1016/S1474-4422(14)70303-5⟩. ⟨inserm-02456704⟩
3 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More